文献速递糖尿病

2022年美国糖尿病的经济成本

Economic Costs of Diabetes in the U.S. in 2022.
PubMed 文献 · Diabetes Care · 2024-01-01

本研究更新了已诊断糖尿病经济负担的估算,基于2022年美国人口 demographics、糖尿病患病率、医疗成本等数据构建经济模型。糖尿病患者年均医疗支出19736美元,其中约12022美元归因于糖尿病,为无糖尿病预期支出的2.6倍。

要点

  • 糖尿病患者年均医疗支出19736美元,其中约12022美元归因于糖尿病,为无糖尿病预期支出的2.6倍。
  • 降糖药物和糖尿病用品约占归因于糖尿病的直接医疗总成本的17%。

核心结论

  • 经通胀调整后,糖尿病直接医疗成本估计较2017年上升7%,较2012年上升35%(以2022年美元计)。
  • 2022年总体估计患病率与2017年相比保持相对稳定,但糖尿病患者绝对人数增长,导致医疗支出增加,尤其是住院和处方药的人均支出。
  • 糖尿病巨大的经济负担继续通过直接医疗和间接成本给社会带来压力。

研究设计与样本

  • 研究结合2022年美国人口 demographics 与来自全国调查数据、流行病学数据、医疗成本数据和经济数据的糖尿病患病率,构建糖尿病经济成本模型,在人群和人均水平估算经济负担。
  • 数据来源包括全国调查(2015-2020年或最近可得数据)、 Medicare 标准分析文件(2020年)以及2018至2021年美国大型商业保险人群的行政索赔数据。

主要发现

  • 在分析的成本类别中,已诊断糖尿病患者的护理占美国医疗保健支出的四分之一,其中61%归因于糖尿病。
  • 糖尿病患者年均医疗支出为19736美元,其中约12022美元归因于糖尿病;糖尿病患者平均医疗支出为无糖尿病预期支出的2.6倍。
  • 降糖药物和糖尿病用品约占归因于糖尿病的直接医疗总成本的17%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study updates previous estimates of the economic burden of diagnosed diabetes, with calculation of the health resource use and indirect costs attributable to diabetes in 2022. RESEARCH DESIGN AND METHODS: We combine the demographics of the U.S. population in 2022 with diabetes prevalence, from national survey data, epidemiological data, health care cost data, and economic data, into a Cost of Diabetes Economic Model to estimate the economic burden at the population and per capita levels. Health resource use and associated medical costs are analyzed by age, sex, race/ethnicity, comorbid condition, and health service category. Data sources include national surveys (2015-2020 or most recent available), Medicare standard analytic files (2020), and administrative claims data from 2018 to 2021 for a large commercially insured population in the U.S. RESULTS: The total estimated cost of diagnosed diabetes in the U.S. in 2022 is $412.9 billion, including $306.6 billion in direct medical costs and $106.3 billion in indirect costs attributable to diabetes. For cost categories analyzed, care for people diagnosed with diabetes accounts for 1 in 4 health care dollars in the U.S., 61% of which are attributable to diabetes. On average people with diabetes incur annual medical expenditures of $19,736, of which approximately $12,022 is attributable to diabetes. People diagnosed with diabetes, on average, have medical expenditures 2.6 times higher than what would be expected without diabetes. Glucose-lowering medications and diabetes supplies account for ∼17% of the total direct medical costs attributable to diabetes. Major contributors to indirect costs are reduced employment due to disability ($28.3 billion), presenteeism ($35.8 billion), and lost productivity due to 338,526 premature deaths ($32.4 billion). CONCLUSIONS: The inflation-adjusted direct medical costs of diabetes are estimated to rise 7% from 2017 and 35% from 2012 calculations (stated in 2022 dollars). Following decades of steadily increasing prevalence of diabetes, the overall estimated prevalence in 2022 remains relatively stable in comparison to 2017. However, the absolute number of people with diabetes has grown and contributes to increased health care expenditures, particularly per capita spending on inpatient hospital stays and prescription medications. The enormous economic toll of diabetes continues to burden society through direct medical and indirect costs.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Parker ED, Lin J, Mahoney T, et al. Economic Costs of Diabetes in the U.S. in 2022. Diabetes Care. 2024. PMID: 37909353. doi:10.2337/dci23-0085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。